Compare Asarfi Hospital with Similar Stocks
Dashboard
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 1.44 times
With a growth in Net Profit of 34.38%, the company declared Very Positive results in Sep 25
With ROCE of 8.6, it has a Attractive valuation with a 2.9 Enterprise value to Capital Employed
Market Beating Performance
Total Returns (Price + Dividend) 
Asarfi Hospital for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Asarfi Hospital Ltd is Rated Buy by MarketsMOJO
Asarfi Hospital Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 05 January 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article
Asarfi Hospital Ltd is Rated Buy
Asarfi Hospital Ltd is rated 'Buy' by MarketsMOJO, a rating that was last updated on 14 Nov 2025. While this rating change took place in mid-November, the analysis and financial metrics discussed here reflect the company’s current position as of 25 December 2025, providing investors with the most up-to-date view of the stock’s fundamentals, returns, and technical outlook.
Read full news article
Asarfi Hospital Sees Revision in Market Evaluation Amid Strong Financials
Asarfi Hospital's market evaluation has undergone a revision reflecting nuanced changes across its financial and technical parameters, despite maintaining a robust performance trajectory in the hospital sector.
Read full news article Announcements 
Closure of Trading Window
27-Dec-2025 | Source : BSEIntimation for closure of Trading Window under security and exchange board of India (PIT) Regulation 2015.
Update Of Group Meeting Of Analyst/Institutional Investor Meetings Held On December 4 2025
05-Dec-2025 | Source : BSEWe hereby inform you that the management of the company met with group of investor held by the Hem Securities Samrudhi 2025- Virtual SME Conclave through virtual mode on Thursday December 42025.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
02-Dec-2025 | Source : BSEThis is to inform you that the Company will be meeting Investors/Analysts on dated November 04 2025 organized by Hem Securities - Samrudhi 2025 Virtual SME Conclave.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 1 FIIs (0.05%)
Harendra Singh (18.78%)
Gopal Singh (2.4%)
30.89%
Quarterly Results Snapshot (Standalone) - Sep'25 - QoQ
QoQ Growth in quarter ended Sep 2025 is 25.77% vs 5.22% in Jun 2025
QoQ Growth in quarter ended Sep 2025 is 34.37% vs -16.45% in Jun 2025
Half Yearly Results Snapshot (Standalone) - Mar'25
Growth in half year ended Mar 2025 is 24.17% vs 22.01% in Sep 2024
Growth in half year ended Mar 2025 is 47.86% vs 107.01% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'24
YoY Growth in nine months ended Dec 2024 is 1.76% vs 6.00% in Sep 2025
YoY Growth in nine months ended Dec 2024 is 12.24% vs -33.58% in Sep 2025
Annual Results Snapshot (Standalone) - Mar'25
YoY Growth in year ended Mar 2025 is 42.86% vs 19.38% in Mar 2024
YoY Growth in year ended Mar 2025 is 160.81% vs -47.51% in Mar 2024






